[
  {
    "ts": null,
    "headline": "Amgen: Likely To Be Rangebound (Rating Downgrade)",
    "summary": "Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives for biotech investors right now.",
    "url": "https://finnhub.io/api/news?id=a3eba74f8d6acab606d02765d5b37e6325e8da5e991ec514a58cd90554167ffd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737378830,
      "headline": "Amgen: Likely To Be Rangebound (Rating Downgrade)",
      "id": 132431396,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630606163/image_1630606163.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives for biotech investors right now.",
      "url": "https://finnhub.io/api/news?id=a3eba74f8d6acab606d02765d5b37e6325e8da5e991ec514a58cd90554167ffd"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN - FDA APPROVES LUMAKRAS IN COMBINATION WITH VECTIBIX FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
    "summary": "THOUSAND OAKS - Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated...",
    "url": "https://finnhub.io/api/news?id=162bdbb03e4debf423de3c6f2c088516a11153aa13029ad575e1aad37ff972cf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737368769,
      "headline": "AMGEN - FDA APPROVES LUMAKRAS IN COMBINATION WITH VECTIBIX FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
      "id": 132430644,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "THOUSAND OAKS - Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated...",
      "url": "https://finnhub.io/api/news?id=162bdbb03e4debf423de3c6f2c088516a11153aa13029ad575e1aad37ff972cf"
    }
  }
]